An Open-Label Extension (OLE) study of Tezacaftor/Ivacaftor (TEZ/IVA) in patients (PTS) ≥ 12 years with cystic fibrosis (CF) Homozygous for F508DEL-CFTR (F/F) or Heterozygous for F508DEL-CFTR and a residual function mutation (F/RF)

Published: Feb 28, 2020
Abstract
Objectives: TEZ/IVA was efficacious and generally safe and well tolerated in pts ≥ 12 y with F/F or F/RF mutations in pivotal Phase 3 studies. EXTEND, a 96-wk OLE study, assessed the long-term safety, tolerability, and efficacy of TEZ/IVA in pts ≥ 12 y with F/F or F/RF genotypes who completed TEZ/IVA parent...
Paper Details
Title
An Open-Label Extension (OLE) study of Tezacaftor/Ivacaftor (TEZ/IVA) in patients (PTS) ≥ 12 years with cystic fibrosis (CF) Homozygous for F508DEL-CFTR (F/F) or Heterozygous for F508DEL-CFTR and a residual function mutation (F/RF)
Published Date
Feb 28, 2020
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.